Tactile Systems Technology, Inc. Q4 2025 Earnings Call Summary

Performance overperformance in Q4 was driven by the simultaneous maturation of investments in sales personnel, CRM technology, and refined go-to-market processes. The sales force reached a strategic 1:1 ratio of account managers to product specialists, optimizing the balance between clinical selling and complex order support. Lymphedema growth was bolstered by the new National Coverage Determination (NCD), allowing eligible Medicare patients to access advanced Flexitouch pumps without first failing ba ...